These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 16391836)

  • 1. Therapeutic effectiveness of bacteriophages in the rescue of mice with extended spectrum beta-lactamase-producing Escherichia coli bacteremia.
    Wang J; Hu B; Xu M; Yan Q; Liu S; Zhu X; Sun Z; Tao D; Ding L; Reed E; Gong J; Li QQ; Hu J
    Int J Mol Med; 2006 Feb; 17(2):347-55. PubMed ID: 16391836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa.
    Wang J; Hu B; Xu M; Yan Q; Liu S; Zhu X; Sun Z; Reed E; Ding L; Gong J; Li QQ; Hu J
    Int J Mol Med; 2006 Feb; 17(2):309-17. PubMed ID: 16391831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
    Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH
    J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia.
    Lee CI; Lee NY; Yan JJ; Lee HC; Ko NY; Chang CM; Wu CJ; Chen PL; Wang LR; Ko WC
    J Microbiol Immunol Infect; 2009 Aug; 42(4):303-9. PubMed ID: 19949753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli.
    Wu UI; Yang CS; Chen WC; Chen YC; Chang SC
    J Microbiol Immunol Infect; 2010 Aug; 43(4):310-6. PubMed ID: 20688291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium.
    Biswas B; Adhya S; Washart P; Paul B; Trostel AN; Powell B; Carlton R; Merril CR
    Infect Immun; 2002 Jan; 70(1):204-10. PubMed ID: 11748184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacteriophage in the treatment of experimental septicemic mice from a clinical isolate of multidrug resistant Klebsiella pneumoniae.
    Vinodkumar CS; Neelagund YF; Kalsurmath S
    J Commun Dis; 2005 Mar; 37(1):18-29. PubMed ID: 16637396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge.
    Rodríguez-Baño J; Navarro MD; Romero L; Muniain MA; de Cueto M; Ríos MJ; Hernández JR; Pascual A
    Clin Infect Dis; 2006 Dec; 43(11):1407-14. PubMed ID: 17083012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular and clinical characterization of plasmid-mediated AmpC β-lactamase-producing Escherichia coli bacteraemia: a comparison with extended-spectrum β-lactamase-producing and non-resistant E. coli bacteraemia.
    Matsumura Y; Nagao M; Iguchi M; Yagi T; Komori T; Fujita N; Yamamoto M; Matsushima A; Takakura S; Ichiyama S
    Clin Microbiol Infect; 2013 Feb; 19(2):161-8. PubMed ID: 22332968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for multidrug resistance in nosocomial bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
    Park SY; Kang CI; Joo EJ; Ha YE; Wi YM; Chung DR; Peck KR; Lee NY; Song JH
    Microb Drug Resist; 2012 Oct; 18(5):518-24. PubMed ID: 22742454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Extended-spectrum β-lactamase producing bacilli in a paediatric hospital].
    Dias A; Oliveira G; Oliveira H; Marques M; Rodrigues F
    Acta Med Port; 2011 Dec; 24 Suppl 2():197-206. PubMed ID: 22849904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli in patients with cancer.
    Ha YE; Kang CI; Cha MK; Park SY; Wi YM; Chung DR; Peck KR; Lee NY; Song JH
    Int J Antimicrob Agents; 2013 Nov; 42(5):403-9. PubMed ID: 24071027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes and risk factors for mortality in community-onset bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli, with a special emphasis on antimicrobial therapy.
    Kang CI; Wi YM; Ko KS; Chung DR; Peck KR; Lee NY; Song JH
    Scand J Infect Dis; 2013 Jul; 45(7):519-25. PubMed ID: 23509913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
    Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for bloodstream infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: A focus on antimicrobials including cefepime.
    Chopra T; Marchaim D; Johnson PC; Chalana IK; Tamam Z; Mohammed M; Alkatib S; Tansek R; Chaudhry K; Zhao JJ; Pogue JM; Kaye KS
    Am J Infect Control; 2015 Jul; 43(7):719-23. PubMed ID: 25934068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy.
    Kang CI; Chung DR; Ko KS; Peck KR; Song JH;
    Ann Hematol; 2012 Jan; 91(1):115-21. PubMed ID: 21556875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for 28-day mortality in elderly patients with extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae bacteremia.
    Ku NS; Kim YC; Kim MH; Song JE; Oh DH; Ahn JY; Kim SB; Kim HW; Jeong SJ; Han SH; Kim CO; Song YG; Kim JM; Choi JY
    Arch Gerontol Geriatr; 2014; 58(1):105-9. PubMed ID: 23988261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival in the environment is a possible key factor for the expansion of Escherichia coli strains producing extended-spectrum β-lactamases.
    Starlander G; Yin H; Edquist P; Melhus Å
    APMIS; 2014 Jan; 122(1):59-67. PubMed ID: 23755901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children.
    Han SB; Jung SW; Bae EY; Lee JW; Lee DG; Chung NG; Jeong DC; Cho B; Kang JH; Kim HK; Park YJ
    Microb Drug Resist; 2015 Apr; 21(2):244-51. PubMed ID: 25398058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum β-lactamase production and its impact on outcome.
    Kim SH; Kwon JC; Choi SM; Lee DG; Park SH; Choi JH; Yoo JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS
    Ann Hematol; 2013 Apr; 92(4):533-41. PubMed ID: 23161391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.